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Cardiovascular riskAbstract Introduction: Thyroid dysfunction and autoantibodies have been frequently associated
with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
Aim of the work: To assess thyroid function and anti-thyroid antibodies in both diseases and elu-
cidate the effects of the thyroid dysfunction on the clinical parameters, disease activity and cardio-
vascular risk.
Patients and methods: Forty SLE and forty RA female patients in addition to twenty controls
were included. Free thyroxine (FT3), free triiodothyronine (FT4), thyroid stimulating hormone
(TSH), anti-thyroid peroxidase antibodies (TPOabs), anti-thyroglobulin antibodies (TGabs), eryth-
rocyte sedimentation rate (ESR), C-reactive protein (CRP), triglycerides (TG), total cholesterol
(TC), low density lipoprotein (LDL), high density lipoprotein (HDL) and intima-media thickness
(IMT) were measured. Disease activities were assessed in both diseases. In RA patients, the
anti-cyclic citrullinated peptide (anti-CCP) was evaluated.
Results: A signiﬁcantly higher TSH level was found in SLE patients compared to RA patients
and controls. No signiﬁcant difference was present between the RA patients and controls.
Anti-TPOabs and anti-TGabs were more frequently detected in SLE (85% and 55%) compared
to RA (50% and 37.5%). Abnormal thyroid function tests were detected in SLE, RA patients
72 H. El-saadany et al.and controls in 52.5%, 17.5% and 10%, respectively. Subclinical hypothyroidism was the most
common abnormality present followed by clinical hypothyroidism then euthyroid sick syndrome
in both SLE and RA patients. A positive anti-CCP and high disease activity score (DAS28) in
RA were among the strongest independent determinants of cardiovascular disease.
Conclusion: Thyroid dysfunction is frequent in SLE and RA patients. Those with thyroid dys-
function had increased cardiovascular risk.
 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society for Joint Diseases and
Arthritis.Open access under CC BY-NC-ND license.1. Introduction
Autoimmune thyroid disease (AITD) is a term used to bring
together a group of pathologies that has thyroid dysfunction
and an autoimmune response against this endocrine organ,
as its hallmark [1,2]. In an attempt to determine the genetic
and environmental factors contributing to autoimmunity, clin-
ical investigators have looked for relations between various
autoimmune disorders such as rheumatoid arthritis (RA) [3],
systemic lupus erythematosus (SLE) [4] Sjo¨gren’s syndrome
[5], scleroderma, vasculitides, [6], alopecia areata [7] and
AITD. In other words, AITD can be regarded as the most
common autoimmune endocrinal disorders [1].
The prevalence of AITD in general population varies be-
tween countries. A prevalence has been described as 5–15%
in women and 1–5%in male [8], meanwhile Helvaci et al. [9]
reported that AITD affects about 2–4% of women and up to
1% of men worldwide, and the prevalence rate increases with
advancing age.
Thyroid dysfunction is common in SLE and RA. Many are
initially treated for thyroid dysfunction before the diagnosis of
lupus or rheumatoid is made or vice versa [10]. Although the
relationship between AITD and both SLE and RA has been
revealed and blamed for precipitating or exacerbating their
symptoms, the prevalence of thyroid disease is controversial
and varied considerably [11]. The clinical presentation varies
among those patients; it can be divided into those that cause
clinical or subclinical hypothyroidism and hyperthyroidism
[12].
Mousa et al. [13] found abnormal thyroid functions in
15.9% SLE and in 8.3% of RA patients and the most common
abnormality was clinical hypothyroidism in 8.3% and 4.1%
then subclinical hypothyroidism in 5.3% and 1.8% of the
SLE and RA patients respectively. However, Assal et al. [14]
reported that thyroid dysfunction was detected in 46.6% of
SLE compared to 16.6% of RA patients and the most common
abnormality was subclinical hypothyroidism followed by clin-
ical hypothyroidism.
Autoimmune thyroid diseases are considered to be organ-
speciﬁc. They are characterized by the presence of auto
antibodies against thyroid speciﬁc components, such as thyro-
globulin, thyroid peroxidase, and the thyrotropin (thyroid
stimulating hormone; TSH) receptor which can either enhance
or block the receptor activity [12]. However, although speciﬁc
to AITD, anti-thyroglobulin (TGabs) [2] and anti-thyroperox-
idase (TPOabs) [2] antibodies have been reported in many pa-
tients with nonthyroidal diseases, and even in the normal
population [3]. On the other hand, a high prevalence of auto
antibodies directed against nonthyroid-speciﬁc antigens has
been described in patients with AITD [4,5]. These observationssuggest that immune reaction of patients with organ-speciﬁc
autoimmune diseases may be polyclonal organ and non or-
gan-speciﬁc auto antigens [5].
Hollowell et al. [15] described a prevalence of 13% for
TPOabs and 11% for TGabs among the general population.
This prevalence rises spontaneously in hypothyroid patients.
Appenzeller et al. [16] reported positive thyroid auto antibod-
ies in the absence of thyroid disease in 17% SLE patients. [4]
However, according to Mousa et al. [13] TPOabs were found
in 19.7% SLE and 10.1% of the RA patients, while TGabs
were found in 8.3% of the SLE and 6% of RA patients. Also
Porkodi et al. [10] found TGabs positive in 82.4% in SLE and
56% in RA patients.
An accelerated progression of atherosclerosis in RA [17]
and SLE [13] patients was already established than in healthy
controls. Moreover SLE and RA patients with thyroid disor-
ders are associated with enhanced risk of cardiovascular dis-
ease (CVD). There is evidence linking the patients with
thyroid dysfunction especially hypothyroidism and the distur-
bance in the lipoprotein metabolism with a signiﬁcant rise in
the low density lipoprotein (LDL). The latter is the main re-
sponder in the development of atherosclerosis, formation of
atheromatous plaques and enhancement of the cardiovascular
risk [18].
However this is not totally explained with the low level of
the thyroid hormone and the associated dyslipidemia, as resto-
ration of the thyroid state does not inﬂuence the occurrence of
the CVD [19]. These ﬁndings demonstrate the fact that the in-
creased CVD in SLE and RA patients with thyroid dysfunc-
tion is complex and not fully clariﬁed [18].
The aim of this study was to assess thyroid function and
anti-thyroid antibodies in SLE and RA patients as well as to
elucidate the possible effects of the thyroid dysfunction on
the clinical parameters, disease activity and assess its impact
as a cardiovascular risk factor.
2. Patients and methods
2.1. Patients
This study included forty SLE female patients aged from 20 to
41 years with a mean age of 28.4 ± 4.9 years, diagnosed
according to the American College of Rheumatology Criteria
(group I) [20], forty female RA patients aged from 23 to
46 years with a mean age of 29.1 ± 6.1 years diagnosed
according to the 2010 ACR/EULAR classiﬁed criteria for
RA [21] (group II). In addition, twenty age-matched healthy
female volunteers served as controls (group III). Age of the
controls ranged from 22 to 43 years with a mean value of
30.9 ± 4.8 years. They were recruited from the outpatient’s
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tion departments, Tanta University Hospitals. Informed con-
sent was obtained from all patients and controls. This study
protocol was approved by the ethics committee of the Faculty
of Medicine, Tanta University.
2.2. Clinical assessment
Patients and controls were subjected to complete history tak-
ing, thorough clinical examination with special attention to:
the presence of symptoms and signs of hyperthyroidism or
hypothyroidism and local examination of the thyroid gland.
Disease activity score was assessed in SLE patients according
to the SLE disease activity index (SLEDAI) [22]. Disease activ-
ity score was assessed in RA patients according to the modiﬁed
disease activity score (DAS 28) [23]. Patients from both groups
were found not to be in a ﬂare of their disease. All patients in
this study were free of immunosuppressant or corticosteroid
medications. Eighteen RA patients were on methotrexate
(10–25 mg/week), ten were on leﬂunomide (20 mg/day) and
twelve on (methotrexate + leﬂunomide). The SLE patients
were on hydroxychloroquine (250 mg twice daily).
Exclusion criteria: Patients with known thyroid disease, un-
der thyroid hormone treatment, patients with any disease
known to affect thyroid function e.g., pituitary adenoma and
pregnant women.
2.3. Biochemical assay
Fasting blood samples were collected in early follicular stage of
the menstrual cycle from patients and controls under aseptic
precautions by venepuncture; 5.0 ml was put into a heparinized
vial for erythrocyte sedimentation rate (ESR) and C-reactive
protein (CRP) measurement. Two to three ml was left in the test
tube to clot for 15 min. The samples were then centrifuged for
10 min at 5000 rpm. The supernatant serum was separated and
divided into 3 aliquots then stored at 70 C till the time of
analysis. Repeated freeze and thaw cycles were avoided.
The following laboratory investigations were performed for
patients and controls: complete blood count (CBC), CRP,
ESR, antinuclear antibodies (ANAS), antidouble stranded
deoxyribonucleic acid (anti-dsDNA), anticyclic citrullinated
peptide (anti-CCP), triglycerides (TG), total cholesterol (TC),
apolipoprotein a, LDL and high density lipoprotein (HDL).
Serum Thyroid Stimulating Hormone (TSH) (normal va-
lue: 0.39–3.55 IU/ml) was assessed using Accu-Bind ELISA
kit (Monobind Inc., Lake Forest, CA 92630, USA), serum free
Thyroxine (FT4) (normal value: 0.8–2 ng/dl) using Accu-Bind
ELISA kit (Monobind Inc., Lake Forest, CA 92630, USA),
serum free triiodothyronine (FT3) (normal value: 2.1–3.8 pg/
ml) using Accu-Bind ELISA kit (Monobind Inc., Lake Forest,
CA 92630, USA), serum thyroid peroxidase antibodies (anti-
TPO) using Accu-Bind ELISA kit (Monobind Inc., Lake For-
est, CA 92630, USA) and serum thyroglobulin antibodies
(anti-TG) using Accu-Bind ELISA kit (Monobind Inc., Lake
Forest, CA 92630, USA).
2.4. IMT of the carotid arteries
All patients underwent B-mode ultrasonography of extra cra-
nial carotid arteries using a 7.5 MHz probe which provides adirect and non-invasive assessment of subclinical atherosclero-
sis through intima-media thickness (IMT) measurement and
detection of atherosclerotic plaques. Common carotid artery
(CCA), internal carotid, and external carotid arteries were
evaluated carefully on both sides. CCA IMT measurements
of the proximal and distal CCA posterior wall were done.
Three measurements were made in a non-neighboring fashion
within an approximately 1 cm segment both from the left and
right CCA proximal and distal portions. IMT values were then
calculated by obtaining the arithmetic means of the measured
values. The mean IMT value for each subject was calculated
using the formula [(Lt IMT+ Rt IMT)/2] and this value
was taken as the measure of the current carotid artery wall
thickness [24].
Statistical analysis: Statistical Package for Social Science
(SPSS) program version 15 was used for an analysis of data.
Data were summarized using mean and standard deviation
(mean ± SD) for quantitative and numbers and percentages
for categorical variables. Student’s–t test was used to com-
pare the difference between the two groups. Chi-square
(v2)–test was used to compare quantitative data. An ANO-
VA test was done to compare the 3 groups. An odds ratio
(OR) and 95% conﬁdence interval (CI) were calculated.
Pearson’s correlation was used to examine the relationships
of the studied parameters. Cardiovascular risk factors were
evaluated by simple regression analysis followed by multiple
linear regressions. p-value <0.05 was considered statistically
signiﬁcant.3. Results
There was reduction in the mean levels of the circulating FT3,
FT4 in both SLE and RA patients compared to the controls
but the difference was statistically insigniﬁcant. The mean level
of TSH was signiﬁcantly higher in SLE patients compared to
the level in RA patients and controls; no signiﬁcant difference
was found between the RA patients and controls. The anti-
TPOabs showed a higher frequency than anti-TGabs in both
S LE and RA patients compared to controls. Also, anti-TPO-
abs were higher in frequency than anti-TG abs in SLE patients
(85% and 55%) compared to the RA patients (50% and
37.5%), respectively (Table 1).
Types and incidence of thyroid dysfunctions in the three
groups are shown in Fig. 1. The frequency of abnormal thyroid
function tests was (52%, 17% and 10%) in SLE, RA patients
and controls, respectively. The difference was statistically sig-
niﬁcant. Subclinical hypothyroidism was the most common
abnormality present (35% and 10%) followed by clinical
hypothyroidism (15% and 5%) then euthyroid sick syndrome
(2.5% and 2.5%) in SLE and RA patients, respectively. Sub-
clinical or clinical hyperthyroidism was not detected in any
SLE or RA patients or controls in this study.
The comparison of the clinical and laboratory parameters
between SLE and RA patients, with and without thyroid
dysfunction is shown in Table 2. SLE and RA patients with
thyroid dysfunction had a signiﬁcant younger age, higher
IMT (Fig. 2), body mass index (BMI), systolic blood pres-
sure (SBP), diastolic blood pressure (DBP), TC, TG, LDL
apolipoprotein a, CRP and lower HDL. Also, RA patients
with thyroid dysfunction had a signiﬁcantly higher DAS28
compared to those without dysfunction; similarly in SLE
Figure 1 Frequency of the different types of thyroid dysfunction in the studied groups.
Table 1 Thyroid hormones and thyroid antibodies in the studied groups.
Mean ± SD SLE patients (n= 40) RA patients (n= 40) Controls (n= 20) p-Value
Thyroid hormones
FT3 2.94 ± 0.51 3.11 ± 0.81 3.6 ± 0.61 0.118
FT4 1.53 ± 0.34 1.73 ± 0.52 1.82±.0.72 0.321
TSH 3.61 ± 3.12 2.81 ± 2.01 2.35 ± 1.52 0.105
Thyroid antibodies
Anti TPO 26.16 ± 10.43 15.98 ± 6.35 7.67 ± 4.15 <0.001*
% 85 50 15 <0.001*
Anti-TG 119.65 ± 89.41 62.12 ± 9.231 31.52 ± 7.13 <0.001*
% 55 37.5 10 <0.001*
FT3: free triiodothyronine; FT4: free thyroxin; TSH: thyroid stimulating hormone; anti-TPO: anti-thyroid peroxidase antibodies; anti-TG: anti-
thyroglobulin antibodies.
* Signiﬁcantly different.
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dysfunction.
Study of the risk factors in SLE and RA patients to develop
thyroid dysfunction revealed that patients with younger age,
positive anti-TPOabs, positive anti-TGabs and high CRP were
at higher risk. Furthermore, in RA patients a positive anti-
CCP and high DAS28 were signiﬁcant risk factors for the
development of thyroid dysfunction (Table 3).
The cardiovascular risk in both SLE and RA patients with
thyroid dysfunctions were studied and the same ﬁndings were
found in both diseases when the regression was performed sep-
arately for each disease. Increased BMI, high SBP, DBP, CRP,
LDL, apolipoprotein a, TG and low HDL were the strongest
independent determinants of the CV D in addition to positive
anti-CCP and high DAS28 in RA patients and higher SLEDAI
in SLE patients (Table 4).4. Discussion
The existence of AITD among patients with systemic autoim-
mune diseases such as RA [3] and SLE [4] has been recorded.
On the other hand, ANA has been frequently detected in pa-
tients with AITD [3]. The mechanism for coexistence of both
AITD, and the two non organ speciﬁc autoimmune diseases,
SLE and RA is unknown, however several mechanisms may
contribute. Auto reactive T cell which can cause primary thy-
roid destruction as well as polyclonal B-cell activation in the
two autoimmune rheumatic diseases may induce autoimmune
thyroiditis and SLE or RA in the same patient [25]. It is also
possible that AITD is secondary to the production of thyrotro-
pin by activated lymphocytes or auto antibodies against the
thyroid, its hormones or receptors [18]. Other factors such as
genetic and environmental factors may be involved. In many
Table 2 Clinical and laboratory parameters in systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients with and
without thyroid dysfunction.
Parameter SLE RA
With thyroid
dysfunction (21)
Without thyroid
dysfunction (19)
p-Value With thyroid
dysfunction (7)
Without thyroid
dysfunction (33)
p-Value
Age (y) 25.21 ± 6.34 34.2 ± 6.8 0.0001* 32.54 ± 9.31 36.3 ± 8.32 0.33
DD (y) 5.1 ± 1.2 4.8 ± 1.6 0.504 7.812 ± 2.36 6.942 ± 3.15 0.495
BMI (kg/m2) 28.15 ± 5.9 23.6 ± 6.2 0.02* 28.454 ± 6.84 22.166 ± 4.82 0.006*
IMT (mm) 1.6 ± 0.3 0.94 ± 0.37 <0.001* 1.14 ± 0.21 0.79 ± 0.23 0.0007*
SBP (mmHg) 152.5 ± 16.7 142 ± 12.35 0.03* 147.21 ± 17.2 131.15 ± 10.35 0.002*
DBP (mmHg) 97.2 ± 7.6 90.4 ± 5.2 0.002* 96.36 ± 5.35 90.254 ± 4.2 0.002*
HDL (mg/dl) 37.3 ± 8.9 45.2 ± 6.32 0.04* 38.15 ± 7.8 43.122 ± 8.32 0.468
LDL (mg/dl) 130.2 ± 26.9 102 ± 20.55 0.001* 126.8 ± 30.24 101.12 ± 25.13 0.023*
TC (mg/dl) 236.2 ± 28.3 220 ± 18.04 0.039* 220.95 ± 29.25 201.45 ± 21.45 0.047*
TG (mg/dl) 181.3 ± 19.2 166 ± 15.21 0.008* 176.22 ± 20.33 152.91 ± 16.45 0.002*
Apo a (mg/dl) 32.22 ± 9.6 38.97 ± 11.8 0.05* 29.8 ± 7.22 22.75 ± 6.76 0.018*
ESR (mm/h) 56 ± 9.4 58.4 ± 8.65 0.41 68.15 ± 12.54 65.125 ± 14.25 0.61
CRP (ng/ml) 25.6 ± 7.1 9.2 ± 2.47 <0.001* 26.24 ± 3.15 10.82 ± 4.2 <0.001*
SLEDAI 9.21 ± 1.4 7.65 ± 2.5 0.018* – – –
DAS28 4. 5 ± 0.45 3.7 ± 0.21 <0.001*
Anti CCP N(%) – – – 6 (85.7%) 20 (60.60%) 0.007*
SLE: systemic lupus erythematosus; RA: rheumatoid arthritis; DD: disease duration; BMI: body mass index; IMT: intima-media thickness;
SBP: systolic blood pressure; DBP: diastolic blood pressure; TC: total cholesterol; TG: triglyceride; HDL: high-density lipoprotein; LDL: low-
density lipoprotein; Apo a: apolipoprotein a; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; SLEDAI: SLE disease activity
index; DAS28: disease activity index; antiCCP: anti-cyclic citrullinated peptide.
* Signiﬁcantly different.
Figure 2 (a) IMT of a control subject (0.6 mm), (b) IMT of an RA patient with thyroid dysfunction (0.98 mm), and (c) IMT of an SLE
patient with thyroid dysfunction (1.79 mm).
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Table 3 Risk factors for thyroid dysfunction in both SLE and RA patients.
Risk factor SLE RA
B p value Odd 95% CI B p value Odd 95% CI
Lower Upper Lower Upper
Age (years) 1.32 0.03* 0.23 0.18 0.35 1.44 0.45 0.43 0.21 2.54
CRP (mg/dl) 0.77 0.04* 2.15 1.51 3.13 0.51 0.015* 1.22 1.01 7.21
Anti TPOabs (IU/ml) 2.79 0.02* 16.3 13.9 21.9 0.52 0.049* 10.9 10.3 11.5
Anti TGabs (IU/ml) 1.28 0.03* 12.1 10.5 14.3 1.08 0.036* 8.72 5.7 10.9
Anti-CCP ‘‘RA’’ – – – 4.16 0.02* 5.56 4.11 7.25
DAS28 – – – 4.52 0.05* 1.26 1.25 3.01
SLEDAI 0.68 0.05* 1.82 1.75 1.92 – – –
CRP: C-reactive protein; TPO: thyroid peroxidase; anti-TG: anti-thyroglobulin; CCP: cyclic citrullinated peptide; DAS28: disease activity score
in 28 joints; B = logistic regression coefﬁcient; CI: conﬁdence interval.
* Signiﬁcance = p< 0.05.
Table 4 Cardiovascular risk factors in SLE and RA patients with thyroid dysfunction (28 patients: 21 SLE and 7 RA) on intima-
media thickness (IMT).
Cardiovascular risk factors IMT of SLE and RA patients with thyroid dysfunction (n= 28)
r p-Value
Age (years) 0.15 0.78
DD (years) 0.25 0.18
BMI 0.78 <0.001*
SBP (mmHg) 0.58 0.035*
DBP (mmHg) 0.64 0.02*
HDL (mg/dl) 0.52 0.037*
LDL (mg/dl) 0.78 <0.001*
TC (mg/dl) 0.22 0.22
TG (mg/dl) 0.55 0.038*
Apo a (mg/dl) 0.65 0.015*
ESR (mm/h) 0.20 0.52
Anti CCP (U/ml) 0.49 0.042*
CRP (ng/ml) 0.82 <0.001*
DAS28 (RA patients) 0.65 0.013*
SLEDAI (SLE patients) 0.53 0.002*
SLE: systemic lupus erythematosus; RA: rheumatoid arthritis; DD: disease duration; BMI: body mass index; IMT: intima-media thickness;
SBP: systolic blood pressure; DBP: diastolic blood pressure; TC: total cholesterol; TG: triglyceride; HDL: high-density lipoprotein; LDL: low-
density lipoprotein; Apo a: apolipoprotein a; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; SLEDAI: SLE disease activity
index; DAS28: disease activity index; antiCCP: anti-cyclic citrullinated peptide.
* Signiﬁcantly different.
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can be seen; also external factors are important such as infec-
tion and stress [26]. Another possible explanation of the pres-
ence of two or more autoimmune diseases in one individual is
microchimerism – the presence of a small number of fetal cells
in the mother as well as maternal cells in the fetus [27].
The results of the present study showed that the mean levels
of serum FT3 and FT4 were lower in the SLE group compared
to RA and control groups but the difference was statistically
insigniﬁcant. On the other hand, the mean levels of TSH was
statistically higher in the SLE group versus both the RA and
control groups, while no signiﬁcant difference was found be-
tween the RA and control groups. This is consistent with the
study of Kakehasi et al. [28] in which an isolated high level
of TSH was the most frequently found abnormality among
SLE patients. Also the study by Zakeri and Sandooghi [11]
concluded that elevated TSH level was the most common
dysfunction in SLE, compared to control group. In the study
of Shahin et al. [29] the mean serum TSH levels in SLE patientswere signiﬁcantly higher than controls, whereas the mean ser-
um FT3 and FT4 levels were signiﬁcantly lower in patients
than in controls.
Regarding our results in RA patients, they come in accor-
dance with that of Chandankhede et al. [30] who demonstrated
that serum T3,T4,TSH levels were not signiﬁcantly different
than the controls while Przygodzka and Filipowicz-Sosnowska
[31] found signiﬁcantly low FT3 concentrations but TSH and
FT4 levels were statistically insigniﬁcant in comparison to
the controls. Assal et al. [14] reported an insigniﬁcant increase
in serum levels of T3, T4, TSH in both SLE and RA patients
compared to controls.
Thyroid auto antibodies are a secondary response to thyroid
injury; together these antibodies increased the diagnostic sensi-
tivity of AITD and possibly other diseases as well. Anti-TPO-
abs are antibodies against thyroid peroxidase enzyme, which
catalyze the iodination of tyrosine and the subsequent biosyn-
thesis of T3 and T4 [32]. Anti-TG abs are antibodies against
thyroglobulin which is produced by the thyroid cells and stored
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TGabs was found in Hashimoto thyroiditis and [33].
In the present work the frequency of the anti-TPO abs was
higher than anti-TG abs in both SLE and RA patients com-
pared to controls and in SLE versus RA patients. Anti-TPO-
abs and anti-TGabs were detected in 85% and 55% in SLE
patients and they were 50% and 37.5% in RA patients, respec-
tively. These results were consistent with Porkodi et al. [10]
who reported the prevalence of anti-TGabs in 82.4% of SLE
and 56% of RA patients. Assal et al. [14] found that anti-TPO-
abs were present in 16% of the SLE and 6%of R A, also TG
abs were found in 6% in SLE, 30% in RA and 10% of controls
but the titer was higher in the patients. On the other hand,
Przygodzka and Sosnowska [31] found no signiﬁcant differ-
ence in the prevalence of either anti-TG and anti-TPO in both
RA patients and controls.
In this work, higher incidence of thyroid dysfunction was
found in SLE and RA patients (52.5% and 17.5%) compared
to the controls (10%). The present study demonstrated that the
incidence of thyroid dysfunction in RA patients was less when
compared to SLE patients. These results were similar to those
reported by Prokidi et al. [10] and Chan et al. [3]. In this work
subclinical hypothyroidism was the most common abnormal-
ity present (35% and 10%) followed by clinical hypothyroid-
ism (15% and 5%) then euthyroid sick syndrome (2.5% and
2.5%) in SLE and RA patients, respectively. Subclinical or
clinical hyperthyroidism was not detected in any SLE or RA
patients or controls in this study. These results strengthen
the hypothesis of slow universal progression of the autoim-
mune process known as a disease pyramid in autoimmune
thyroiditis in which patients’ progress from subclinical hypo-
thyroidism to clinical hypothyroidism in approximately one
quarter of the case over time. SLE and RA especially with
anti-TPO positive patients may accelerate progression of this
disease pyramid [3,18].
The results of this study came in accordance with those of
Assal et al. [14] who concluded that the most common abnor-
mality in both SLE and RA patients was subclinical hypothy-
roidism followed by clinical hypothyroidism. Appenzeller et al.
[16] observed that subclinical hypothyroidism was more fre-
quent among SLE patients (11.5%) than in controls. Similarly,
Kakehasi et al. [28] concluded that subclinical hypothyroidism
was the most common diagnosis (10%), followed by clinical
hypothyroidism (4%) and then subclinical hyperthyroidism
(2%). On the other hand, Kumar et al. [34] reported that clin-
ical hypothyroidism was the commonest dysfunction (14%)
followed by subclinical hypothyroidism (12%). On the con-
trary, Antonelli et al. [19] reported a signiﬁcantly higher prev-
alence of Graves’ disease and clinical hypothyroidism in SLE
patients than in controls.
The results of RA patients were in accordance with the re-
sult of Raterman et al. [18] who found high prevalence of sub-
clinical hypothyroidism in RA patients. However Porkodi
et al. [10] found that clinical hypothyroidism (73.2%) was
the most common abnormality followed by subclinical hypo-
thyroidism (17.1%) and hyperthyroidism (7.3%). In contrast,
Yavasoglu et al. [17] found no differences between patients
with RA and controls. The differences in these results could
be explained by racial differences, patient selection (age and
Sex), size of sample, duration of follow up, inﬂuence of medi-
cations and diagnostic methods for the detection of thyroid
disorders [14].In the present work, SLE and RA patients with thyroid
dysfunction had a signiﬁcant younger age and higher IMT,
BMI, SBP, DBP, TC,TG, LDL, apolipoprotein a, CRP and
lower HDL as well as positive anti-CCP titer and a higher
DAS28 in RA patients. This coincided with the study of Mou-
sa et al. [13] who found that SLE and RA patients with thyroid
dysfunction had a signiﬁcant higher BP, LDL, CRP and apo-
lipoprotein a. Also, Cojocaru-Goﬁta et al. [35] found that RA
patients with thyroid dysfunction was associated with the
occurrence of positive anti-CCP titer and Kang et al. [36]
who found that women with RA and hypothyroidism had a
higher DA S28 compared to women with RA without
hypothyroidism.
In this study, it was observed that, SLE and RA patients
with a signiﬁcant higher BMI, SBP DBP, CRP, triglycerides,
LDL and low levels of HDL had increased incidence to devel-
op thyroid dysfunction These results came in accordance with
Mousa et al. [13]. Also there was an association of the anti
CCP positive RA patients and high DAS28 with thyroid
dysfunction this trend has been observed in the study of
Yavasoglu et al. [17]. Similarly in SLE patients there is associ-
ation between SLEDAI with the thyroid dysfunction which is
consistent with the study of Appenzeller et al. [16].
In this work, there was an increased incidence of the CVD
in both SLE and RA patients with thyroid dysfunction, the in-
crease in BMI, SBP, DBP, LDL, apolipoprotein a, TG, CRP
and decrease in HDL were the strongest independent determi-
nants of CVD in both diseases and also positive anti-CCP and
high DAS28 in RA. These results coincided with the results of
Rolda´n et al. [37] and Raterman et al. [18] who found a higher
risk of CVD in RA patients with clinical hypothyroidism in
comparison with the euthyroid RA patients. Also Mousa
et al. [13] found an increased CVD in SLE and RA patients
with thyroid dysfunction.
The increased incidence of CV risk factors is not totally ex-
plained with the traditional risk factors. It may be attributed to
the low grade systemic inﬂammation present with AITD, RA
and SLE which plays a central role in the development of ath-
erosclerosis. Chronic inﬂammation promotes the increase in
inﬂammatory parameters and cytokines, with activation of
vascular and endothelial cell dysfunction, and impaired nitric
oxide availability leading to decreased compliance of the vessel
and the appearance of atheromatous plaque, independent of li-
pid proﬁle alterations [25]. Mousa et al. [13] concluded that a
relationship exists between poly-autoimmunity and the occur-
rence of CVD which is not exactly explained.
Silent autoimmune thyroid diseases occurred more fre-
quently in association with SLE than RA patients. Subclinical
hypothyroidism followed by clinical hypothyroidism was the
most common dysfunctions detected. Elevated antibody titers
may reﬂect an epiphenomenon of the underlying autoimmune
disorders and play an additive role in the development of the
thyroid dysfunction in those patients. The presence of auto
antibodies suggests autoimmunity to be the basis for thyroid
dysfunction in SLE and RA patients. Anti thyroid antibodies
were more frequent in SLE than in RA patients. Anti-TPOabs
were more frequent compared to anti-TG abs and they may
help in early detection of associated thyroid disorders. The in-
creased CVD in SLE and RA patients with thyroid dysfunc-
tions is not fully clariﬁed.
It is important to identify thyroid dysfunction in SLE (in
particular) and RA patients and treat them accordingly by
78 H. El-saadany et al.assessment of the thyroid function and measurement of the
thyroid antibodies as a part of the routine biochemical and
immunological proﬁle since the course of thyroid disease is of-
ten asymptomatic. Further studies on a large number of pa-
tients are needed to clarify the previous points and to ensure
the correlation between the thyroid dysfunctions and the dif-
ferent clinical variable of the SLE and RA patients especially
the risk factors of CVD.Conﬂict of interest
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